Translational Sciences Corp., a Cambridge medical software firm, has won FDA approval to commercialize its OncoTrac medical imaging software, intended for assessing treatment options for metastatic tumors.
Quantitative assessments coming out of OncoTrac software may be used by companies in submitting data for FDA approval of anti-cancer drugs. According to the company, its assessments conform to clinical research standards and can be used by oncologists, radiologists and cancer patients alike. The data is exported and stored in electronic medical records and a Picture and Archive Communications System.
Originally developed at the German Cancer Research Center by Mint Medical GmbH, Translational Sciences OncoTrac is approved in Europe where it is sold as Mint Lesion.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.